Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the most recent global pandemic that has caused more than a million deaths around the world. The spike glycoprotein (S) drives the entry and fusion of this virus and is the main determinant of cell tropism. To explore S requirements for entry under BSL2 conditions, S has been pseudotyped onto vesicular stomatitis virus (VSV) or retroviral particles with varied success. Several alterations to S were demonstrated to improve pseudoparticle titers, but they have not been systematically compared. In this study, we produced pseudotyped VSV particles with multiple modifications to S, including truncation, mutation, and tagging strategies. The main objective of this study was to determine which modifications of the S protein optimize cell surface expression, incorporation into pseudotyped particles, and pseudoparticle entry. Removal of the last 19 residues of the cytoplasmic tail produced a hyper-fusogenic S, while removal of 21 residues increased S surface production and VSV incorporation. Additionally, we engineered a replication-competent VSV (rVSV) virus to produce the S-D614G variant with a truncated cytoplasmic tail. While the particles can be used to assess S entry requirements, the rVSV∆G/SMet1D614G∆21 virus has a poor specific infectivity (particle to infectious titer ratio).
Withdrawal statement: The authors have withdrawn this manuscript due to a duplicate posting of manuscript number BIORXIV/2024/592122. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author. The correct preprint can be found at doi: https://doi.org/10.1101/2024.05.01.592122 .
10 September 2026 in Journal of Experimental Medicine
Intranasal vaccination elicits CD8 tissue-resident memory T cells (TRM) throughout the respiratory tract that provide cross-protection against heterosubtypic viral strains and reduce immunopathology. We previously demonstrated that CD8 TRM can reduce the probability of respiratory virus transmission and the magnitude of infection, using a murine model of parainfluenza virus transmission. Here, we show that CD8 TRM-mediated protection occurs independently of circulating leukocytes, B cells, or CD4 T cells. Additionally, we investigate the contributions of CD8 TRM in different respiratory tract compartments and illustrate that CD8 TRM in the upper respiratory tract (URT), but not the lower respiratory tract (LRT), become activated and proliferate in response to transmitted virus. Furthermore, we demonstrate that CD8 TRM in the URT alone provide sufficient immune surveillance to prevent propagation of infection after viral transmission. These findings offer insights into the development of T cell–based respiratory virus vaccines and shed light on the critical role of URT CD8 TRM in the prevention of viral transmission.